Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hit to Lead

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2 result(s) found for: Hit to Lead. Displaying page 1 of 1.
    EudraCT Number: 2007-000128-42 Sponsor Protocol Number: HIT-HGG-2007 Start Date*: 2009-03-19
    Sponsor Name:Martin-Luther-University Halle-Wittenberg
    Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole...
    Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030288 Oligodendroglioma malignant LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066254 Gliomatosis cerebri PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026659 Malignant oligodendroglioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018340 Gliosarcoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060971 Astrocytoma malignant PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017701 Ganglioglioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003572 Astrocytoma malignant NOS LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008093 Cerebral astrocytoma, high grade LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003716-12 Sponsor Protocol Number: C34004 Start Date*: 2017-07-18
    Sponsor Name:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:26:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA